This clinical trial is focused on studying a type of prostate cancer known as metastatic castration-resistant prostate cancer (mCRPC). This is a form of prostate cancer that has spread to other parts of the body, particularly the bones, and continues to grow even when the amount of testosterone in the body is reduced to very low levels. The study is comparing two treatments: Radium-223 dichloride (Xofigo), which is a treatment that emits radiation to help kill cancer cells, and a new type of treatment that inactivates hormones, known as novel anti-hormonal therapy (NAH). The purpose of the study is to assess the overall survival of patients receiving Radium-223 dichloride compared to those receiving a second line of NAH.

Participants in the study will receive either Radium-223 dichloride or one of the NAH treatments, which may include medications such as abiraterone acetate (Zytiga), enzalutamide (Xtandi), prednisone, or prednisolone. These medications are taken orally, except for Radium-223 dichloride, which is given as an injection. The study will monitor the participants over a period to observe the effects of the treatments on their cancer and overall health. The study will also look at other factors such as the time it takes for symptoms to worsen, any side effects experienced, and the impact on the participants’ quality of life.

This trial aims to provide valuable information on the effectiveness and safety of Radium-223 dichloride compared to NAH in treating patients with mCRPC. By participating in this study, researchers hope to better understand which treatment option may offer the best outcomes for patients with this type of prostate cancer.